Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619247 | 1.00 | PDK2 (0.38) | PDK2HRH3CYP2D6KCNH2MAOB | |
| SCHEMBL620079 | 0.91 | HRH3 (0.42) | PDK2HRH3CYP2D6KCNH2 | |
| SCHEMBL620080 | 0.91 | HRH3 (0.42) | PDK2HRH3CYP2D6KCNH2 | |
| SCHEMBL619822 | 0.83 | KDM4E (0.43) | — | |
| SCHEMBL619821 | 0.83 | KDM4E (0.43) | — | |
| SCHEMBL619691 | 0.81 | KDM4E (0.45) | — | |
| SCHEMBL620167 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL620168 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL618064 | 0.76 | MAOB (0.52) | PDK2MAOB | |
| SCHEMBL618063 | 0.76 | MAOB (0.52) | PDK2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-7842703-B2 | Substituted benzofused derivatives and their use as vanilloid receptor ligands | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV6 | PDK2 898/4885HRH3 424/4885CYP2D6 983/4885 |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | PDK2 918/4885HRH3 310/4885CYP2D6 965/4885 |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | PDK2 898/4885HRH3 424/4885CYP2D6 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.